Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Estrogen receptor responsive long non-coding RNA 1 (ERLNC1)
- Target
- ERLNC1
- Molecular classification
- Other (Long non-coding RNA)
01
Overview
Estrogen receptor responsive long non-coding RNA 1 (ERLNC1, also known as ElncRNA1 and TC0101441) is a long non-coding RNA (lncRNA) newly identified in the context of several cancers. It is upregulated in gastric cancer and epithelial ovarian cancer tissue compared to normal tissue, and high ERLNC1/TC0101441 expression is associated with increased risk of lymphatic metastasis and poor survival in gastric cancer patients. Its gene is regulated by estrogen receptor signaling pathways, suggesting a mechanistic link to hormone-sensitive cancers, but it does not encode a protein or serve as a direct therapeutic target. Rather, it is emerging as a promising biomarker for diagnosis and prognosis in some malignancies.
- Other names
- ElncRNA1TC0101441Oestrogen-induced long non-coding RNA-1
02
Mechanism of action
Does not serve as a direct drug target. Acts via regulation of gene expression and may influence cancer progression and patient prognosis through modulation of cell proliferation, migration, and invasion
03
Biological functions
Regulation of cell proliferationRegulation of cell migration and invasionPotential modulation of metastasis
04
Disease associations
Cancer (notably gastric cancer, ovarian cancer, and endometriosis)Possible involvement in metastasis
05
Biomarkers
TC0101441/ERLNC1 expression is reported as a diagnostic and prognostic biomarker in gastric cancer (GC), with high expression associated with poorer survival and lymphatic metastasis
Beyond the preview
Go deeper on Estrogen receptor responsive long non-coding RNA 1 (ERLNC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Estrogen receptor responsive long non-coding RNA 1 (ERLNC1).